Amanote Research
Register
Sign In
P3.01-16 Low Dose Apatinib Combined With EGFR-TKI in Treating Advanced NSCLC After First-Generation EGFR-TKIs Treatment Failure
Journal of Thoracic Oncology
- United States
doi 10.1016/j.jtho.2018.08.1576
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Oncology
Respiratory Medicine
Pulmonary
Date
October 1, 2018
Authors
M. Chen
J. Song
W. Liu
Publisher
Elsevier BV
Related search
P1.01-60 Preventing and Treating Brain Metastases With Three First-Line EGFR-TKI in Patients With EGFR Mutation Advanced NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Comparison of EGFR-TKI and Chemotherapy in the First-Line Treatment of Advanced EGFR Mutation-Positive NSCLC
Neoplasma
Cancer Research
Combination of EGFR-TKIs With Chemotherapy Versus Chemotherapy or EGFR-TKIs Alone in Advanced NSCLC Patients With EGFR Mutation
Biologics: Targets and Therapy
Oncology
Immunology
Gastroenterology
Pharmacology
Rheumatology
Allergy
P1.13-21 Clinical Efficacy and Safety of Apatinib Combined With EGFR - TKIs in Advanced Non-Small Cell Lung Cancer With EGFR - TKIs Resistance
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P3.01-111 Efficacy and Safety of Cytotoxic Drug Chemotherapy After First-Line EGFR-TKI in Elderly Patients With NSCLC Harboring Sensitive EGFR Mutations
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Switching From First or Second Generation EGFR-TKI to Osimertinib in EGFR Mutation-Positive NSCLC
Lung Cancer Management
P2.13-23 Osimertinib Treatment Result of Plasma T790M Positive in Different Clinical Failure Modes After First-Line EGFR TKI for EGFR Mutant NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
First-Line Treatment in NSCLC Harboring EGFR Common Mutations: EGFR TKI in Monotherapy or in Combination With Anti-Vegf?
Expert Review of Anticancer Therapy
Oncology
Pharmacology
Bisphosphonates Enhance Antitumor Effect of EGFR-TKIs in Patients With Advanced EGFR Mutant NSCLC and Bone Metastases
Scientific Reports
Multidisciplinary